BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28782449)

  • 1. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.
    Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA
    J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Economic Burden Associated with Transplantation-Related Complications.
    Perales MA; Bonafede M; Cai Q; Garfin PM; McMorrow D; Josephson NC; Richhariya A
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1788-1794. PubMed ID: 28688917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
    Bonafede M; Anaissie E; Evans K; Itzler R
    BMC Health Serv Res; 2021 Oct; 21(1):1125. PubMed ID: 34666775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
    Watson C; Xu H; Princic N; Sruti I; Barlev A
    J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
    Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
    J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of sarcoidosis in a commercially-insured population in the United States.
    Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
    J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.
    Wang SX; Ganguli AX; Bodhani A; Medema JK; Reichmann WM; Macaulay D
    J Med Econ; 2017 Dec; 20(12):1299-1306. PubMed ID: 28880733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals.
    Dhakal B; Giri S; Levin A; Rein L; Fenske TS; Chhabra S; Shah NN; Szabo A; D'Souza A; Pasquini M; Hari P; Hamadani M
    JAMA Netw Open; 2019 Jul; 2(7):e196476. PubMed ID: 31276175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
    Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
    J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database.
    Majhail NS; Mau LW; Denzen EM; Arneson TJ
    Bone Marrow Transplant; 2013 Feb; 48(2):294-300. PubMed ID: 22773126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis.
    Al Sawah S; Foster SA; Goldblum OM; Malatestinic WN; Zhu B; Shi N; Song X; Feldman SR
    J Med Econ; 2017 Sep; 20(9):982-990. PubMed ID: 28635342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
    Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
    J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population.
    Lee S; Xie L; Wang Y; Vaidya N; Baser O
    J Med Econ; 2018 Jun; 21(6):564-570. PubMed ID: 29359606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
    Hagiwara M; Sharma A; Chung KC; Delea TE
    J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of second allogeneic hematopoietic cell transplantation.
    Khera N; Storer B; Sandmaier BM; Chapko MK; Lee SJ
    Transplantation; 2013 Jul; 96(1):108-15. PubMed ID: 23694949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective.
    Maziarz RT; Gergis U; Edwards ML; Song Y; Liu Q; Anderson A; Signorovitch J; Manghani R; Simantov R; Shin H; Sivaraman S
    Blood Adv; 2024 Mar; 8(5):1200-1208. PubMed ID: 38055922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.